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In many human diseases, the presence of inflammation is associated with an increase in the level of reactive oxygen
species (ROS). The resulting state of oxidative stress is highly detrimental and can initiate a cascade of events that
ultimately lead to cell death. Thus, many therapeutic attempts have been focused on either modulating the immune
system to lower inflammation or reducing the damaging caused by ROS. Berlin et al. reported the development of a
novel nanoantioxidant known as poly(ethylene glycol)-functionalized-hydrophilic carbon clusters (PEG-HCCs). They
showed that PEG-HCCs could be targeted to cancer cells, utilized as a drug delivery vector, and can even be visual-
ized ex vivo. Our work here furthers this work and characterizes Gd-DTPA conjugated PEG-HCCs and explores the
potential for in vivo tracking of T cells in live mice. We utilized a mouse model of delayed-type hypersensitivity
(DTH) to assess the immunomodulatory effects of PEG-HCCs. The T1-agent Gd-DTPA was then conjugated to the
PEG-HCCs and T1 measurements, and T1-weighted MRI of the modified PEG-HCCs was done to assess their relaxivity.
We then assessed if PEG-HCCs could be visualized both ex vivo and in vivo within the mouse lymph node and spleen.
Mice treated with PEG-HCCs showed significant improvements in the DTH assay as compared to the vehicle (saline)-
treated control. Flow cytometry demonstrated that splenic T cells are capable of internalizing PEG-HCCs whereas
fluorescent immunohistochemistry showed that PEG-HCCs are detectable within the cortex of lymph nodes. Finally,
our nanoantioxidants can be visualized in vivo within the lymph nodes and spleen of a mouse after addition of
the Gd-DTPA. PEG-HCCs are internalized by T cells in the spleen and can reduce inflammation by suppression of a
recall immune response. PEG-HCCs can be modified to allow for both in vitro and in vivo visualization using MRI.
© 2016 The Authors. NMR in Biomedicine published by John Wiley & Sons Ltd.
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INTRODUCTION
A multitude of human diseases including diabetes, cancers and
neurogenerative diseases are associated with inflammation and
increased production of free radicals resulting in a state of oxida-
tive stress (1–4). These hallmarks of inflammation and ROS eleva-
tion have been shown to cause damage to tissues and organs by
damaging organelles and cell components such as mitochon-
dria, DNA, lipids and proteins (5–7). Once this cascade of events
has been initiated, the result is typically apoptosis and in the
case of neurodegenerative disease, the loss of irreplaceable
neurons (1–4,6,7). As a result, much time and research have been
spent studying how to mitigate inflammation and oxidative stress
using immunomodulatory drugs and antioxidants, respectively.
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Thenovel nanoantioxidants usedwithin this study are poly(ethylene
glycol)-functionalized-hydrophilic carbon clusters (PEG-HCCs) (8,9).
PEG-HCCs were first developed and described by Lucente-Schultz
et al. 2009 and are derived from ultra-short, single-walled carbon
nanotubes that are heavily oxidized, water soluble and approxi-
mately 40nm in length and 2–3nm wide. PEG moieties are added
to their sidewalls for improved biodistribution. Berlin et al. (10) then
demonstrated the flexibility of these nanoantioxidants in that their
side walls could be non-covalently functionalized with antibodies
and also demonstrated their effectiveness as an in vitro antioxidant
(10). Their work showed that PEG-HCCs were highly effective at
scavenging oxygen radicals, more so than trolox, a vitamin E ana-
log (8). They have been utilized in vivo, within a rat model of trau-
matic brain injury (TBI), where Bitner et al. showed that PEG-HCCs
improve cerebral blood flow post-TBI via the scavenging of super-
oxide molecules (9). Finally, aside from their antioxidant capacity,
PEG-HCCs have also been utilized as a targeted vector for the trans-
port of paclitaxel, an anti-cancer medication, to tumor cells by the
non-covalent addition of antibodies to their side-walls (10). Most
striking of all in these studies is the lack of toxicity in cells, mice
or rats. This exquisite safety profile is probably as a result of their
ultra-short, ultra-small size (approximately the size of proteins), a
high degree of oxidation, undetectablemetal content, water solubil-
ity, high dispersion and low aggregation owing to PEGylation (10).
The field of cell labeling, specifically of T cell labeling, has
worked towards developing an agent that will allow the longitu-
dinal tracking of T cells in an in vivo system using MRI. Thus far,
studies have shown that T cells can be labeled in vitro with
several agents such as superparamagnetic iron oxide particles
(SPIOs) or a novel perfluoropolyether (PFPE) nanoparticle
(11–13). As signal intensity is dependent on the levels of loading
within the cells, they must be loaded in vitro to ensure high
levels of loading. Labeled cells are then adoptively transferred
into the animal for imaging. Unsurprisingly, there are some
drawbacks to these methods. In both cases, there are biocom-
patibility concerns. In the case of the SPIOs, there is difficulty
distinguishing the signal from background and artifacts due to
the T2* nature of SPIO imaging (12,13). In the case of PFPE, the
signal intensity is low, even when cells are pre-loaded with the
agents and adoptively transferred. There is also a loss of signal
as cells divide (11,14). Finally, there is still limited uptake by T cells
versus uptake bymonocytes, which is speculated to be because of
the smaller size and lower phagocytic function of T cells compared
with that of monocytes (11–14). Thus, there is still a need for a T
cell-specific labeling agent that has a high signal, i.e. T1-agent.
As we worked to characterize the PEG-HCCs, we discovered
that upon subcutaneous administration of our nanoantioxidants,
they localized within the draining lymph nodes in a reproducible
and very specific pattern. This pattern coincided with the cortex
of the lymph nodes. Consequently, we became interested in ver-
ifying whether the PEG-HCCs were localizing within T cells and
could be utilized as a T cell labeling agent. To assess the ability
of PEG-HCCs to affect T cells, we first used a mouse model of
delayed-type hypersensitivity (DTH). DTH is an inflammatory
response mediated by T cells and antigen-presenting cells such
as macrophages or dendritic cells. The recall immune reaction ob-
served during DTH is similar to that leading to pancreatic beta cell
death in type-1-diabetes and demyelination in multiple sclerosis.
This study adds a number of new and important characteris-
tics to the lengthening list of PEG-HCC functions in that they (i)
suppress the recall immune response in vivo, (ii) enter the cortex
of lymph nodes and the spleen, (iii) are internalized by splenic T
cells and (iv) can be modified with the addition of gadolinium
complexed to diethylene triamine pentaacetic acid ([Gd]DTPA)
for in vivo visualization utilizing MRI. We report our findings of
treating mice with PEG-HCCs and make new observations as to
their localization within immune organs, i.e. lymph node and
spleen both in vivo and ex vivo. Our findings not only indicate
that these nanoantioxidants can modulate the immune system
but also can be monitored both ex vivo and in vivo via the
addition of an MR-detectable moiety.
METHODS
Preparation of PEG-HCCs and [Gd]DTPA-PEG-HCCS
DTPA-PEG-HCCs, prepared as previously described by Berlin et al.
2010 (10), were placed in a vial (5mL, 314mg/L HCC core). An
aqueous solution of GdCl3•6 H2O (Sigma-Aldrich (St. Louis, MO, USA),
12mg in 100μL DI H2O) was added to this vial. The solution
was then vortexed for 5min then allowed to stand for 30min before
it was passed through a PD-10 column to remove excess Gd3+.
Mice
All mice utilized for this work were C57Bl/6 J (Jackson Laboratory
Bar Harbor, ME, USA) approximately 10–15weeks of age. Animal
housing and handling were in compliance with NIH Guidelines for
the Care and Use Laboratory Animals. Animal protocols were ap-
proved by The Institutional Animal Care andUse Committee (IACUC)
at Baylor College of Medicine before any work was carried out.
Mouse treatment paradigm and lymph node and spleen
collection
All mice were treated under anesthesia, i.e. 5% isoflurane and
100% oxygen. For lymph node imaging, C57Bl/6 J mice were
given subcutaneous injections near the base of the tail of 200
μL of PEG-HCC (300 g/L), [Gd]DTPA-PEG-HCC (300mg/L), 5mM
Magnevist® (Bayer HealthCare, Wayne, NJ, USA) or vehicle (saline
Butler Schein, Dublin, OH, USA) near the base of the tail. For
spleen MR and flow cytometry experiments, mice were, respec-
tively, given scapular subcutaneous injections of 200 μL of [Gd]
DTPA-PEG-HCCs (200mg/L), PEG-HCC (200mg/L) or the vehicle.
Twenty-four hours post-injection, mice were anesthetized using
5% isoflurane and oxygen and sacrificed using cervical disloca-
tion. Inguinal and axillary lymph nodes were then removed and
either embedded in 1% agarose for MR imaging or placed in
10% formalin for histology. The spleens were also harvested
24 h post-injection and prepared for flow cytometry. For spleen
MR experiments, mice were sacrificed as above, and the spleens
were imaged in the intact mouse.
Flow Cytometry
Spleens harvested from mice were placed in ice-cold calcium and
magnesium free 1X Dulbecco’s phosphate-buffered saline (DPBS
Cellgro, Manassas, VA, USA). A single-cell suspension of splenocytes
was created of the spleen in 15mL of 1X DPBS and straining the
mixture through a 70-μm cell strainer. Cells were then counted
using a hemacytometer and a total of 2.5 x 105 cells were used
for each experimental condition. Experimental conditions were as
follows: samples from PEG-HCC and vehicle-treated animals were
either kept intact during wash and incubation steps, using a buffer
composed of 1X DPBS with 2% goat serum and 2% bovine serum
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albumin (BSA Santa Cruz Biotechnology, Dallas, TX, USA) or
permeabilized using the previously indicated buffer with the
addition of 0.5% saponin (Sigma-Aldrich, St. Louis, MO, USA).
After counting, cells were stained with a primary rabbit
antibody against PEG (Abcam ab51257 Cambridge, MA, USA) at
1:803 in addition to a primary antibody against CD3 conjugated
to allophycocyanin (APC; Ebioscience 17–0032 San Diego, CA,
USA) at 1:80. Cells were then washed in their respective buffers
and stained with an anti-rabbit Alexa Fluor 488 antibody (Life
Technologies A11034 Carlsbad, CA, USA) and washed again. Af-
ter washing, cells were fixed in ice-cold 1X DPBS with 1%
paraformaldehyde and stored at 4 °C until data acquisition.
Data were acquired on a Becton Dickinson Canto II cell
analyzer. Compensation controls included unstained intact cells,
intact cells incubated with Alexa Fluor 488-conjugated CD45R
(Invitrogen RM2620 Carlsbad, CA, USA), and intact cell incubated
with an APC-conjugated CD3 antibody. Intact and permeabilized
samples incubated with APC-conjugated CD3 and Alexa Fluor 488
secondary served as controls to remove the background PEG signal.
Data were analyzed using FloJo (Treestar) and statistical anal-
ysis was performed with a two-way ANOVA with a Tukey multi-
ple comparisons test.
Histology
To assess the localization of [GD]DTPA-PEG-HCCs within lymph
nodes, we carried out immunohistochemistry of lymph node col-
lected [Gd]DTPA-PEG-HCC and vehicle-treated mice. Lymph nodes
were placed in 10% buffered formalin immediately after collection
and embedded in paraffin for sectioning. Lymph node sectionswere
deparaffinized and rehydrated using the following gradient: 100%
xylene (3X 3min), 1:1 (v/v) ratio of 100% ethanol to 100% xylene
(1X 3min), 100% ethanol (1X 3min), 95% ethanol (1X 3min), 80%
ethanol (1X 3min), 70% ethanol (1X 3min) and deionized tap water
(2X 3min). Heat-mediated antigen retrieval was then performed by
microwave heating slides in a Tris-EDTA buffer for 20min after which
sections were blocked for 2h at room temperature in a solution of
1X Tris-buffered saline (TBS) with 1% BSA and 10% normal goat se-
rum. After blocking, slides were then incubated with blocking buffer
(1% BSA in TBS) containing primary antibodies against the T-cell sur-
face marker CD3 (Abcam ab11089 Cambridge, MA, USA) and PEG
(Abcam ab51257 Cambridge, MA, USA) at 1:100 overnight at 4 °C
in a humidified box. Slides were then washed in 1X TBS twice for
5min each, then were incubated with blocking buffer containing
anti-rat Alexa Fluor 488 (Abcam ab150157 Cambridge, MA, USA)
and anti-rabbit Alexa Fluor 568 (Abcam ab175471 Cambridge, MA,
USA) at 1:100 for 1h at room temperature. Slides were then washed
(3X 5min) in TBS, dried and mounted with media containing DAPI.
Finally, images were taken using an Olympus 1X71 microscope
(Tokyo, Japan).
Delayed-type hypersensitivity (DTH) induction and
monitoring
Active DTH was carried out as previously described by Beeton et al.
(15). Briefly, 10-week-old, female C57Bl/6 J mice were immunized
against ovalbumin (OVA) using an emulsion consisting of a 1:1 ratio
of Complete Freund’s Adjuvant (Difco, Sparks, MD, USA) and OVA
(Sigma-Aldrich, St. Louis, MO, USA). Each mouse received100 μL
emulsion at the base of the tail (100μg OVA/mouse). Before immu-
nization, mice were treated intravenously with 100μl of PEG-HCCs
(300mg/L) or vehicle once a week for 5weeks. One week after
immunization, mice were challenged with 10μL of a 2mg/mL solu-
tion of OVA in the pinna of one ear and a solution of the vehicle in
the other. One day after challenge, the ear thickness was measured
using a spring-loaded micrometer and the difference in size be-
tween the vehicle-treated ear and the OVA-treated ear was used
as a measure of inflammation. Data from DTH assay were analyzed
by one-way ANOVA with Tukey’s multiple comparisons test
(GraphPad Prism La Jolla, CA, USA).
Ex Vivo and In vivo MRI
We assessed whether [GD]DTPA-PEG-HCCs could be visualized
using T1-weighted MR scans within a mouse lymph node and
spleen both ex vivo and in vivo. Mice were treated with 100μL
of 200mg/L concentration PEG-HCC, [Gd]DTPA-PEG-HCC, 5mM
Magnevist® or vehicle as described previously. Twenty-four
hours post-injection, mice were anesthetized with 5% isoflurane
and 100% oxygen, placed in the animal holder (Bruker BioSpin,
Billerica, MA, USA) and kept under 2% isoflurane and oxygen
and imaged using 9.4 T, Bruker Avance BioSpec Spectrometer with
a 21-cm horizontal bore (Bruker BioSpin Billerica, MA, USA) and a
35-mm resonator. During imaging, breathing was monitored, and
the body temperature was kept at 37 °C using an animal heating
system (SA Instruments, Stony Brook, NY, USA). After imaging, mice
were removed from the MRI and placed on a heating pad until
they woke up, after which they were placed back into their cages.
Protocol for MR scans
Mice were imaged using a Rapid Acquisition with Refocused Ech-
oes (RARE) protocol to obtain T1-weighted images with the fol-
lowing parameters: TE = 11.72ms, TR = 590.94ms, FOV= 25mm,
matrix size =256 x 256, taking 2min, 31 s and 280ms. T1-mea-
surements were done using a RARE protocol with a Variable Ac-
quisition Time (RAREVTR) as described by (16) with the following
parameters: TE = 10ms, TR = 200–6000ms, FOV= 20mm, matrix
size =128 x 128, taking 4min, 3 s and 200ms. Ex vivo and
in vivo scans were carried out using a RARE protocol with the fol-
lowing parameters: TE = 7.51ms, TR = 1500ms, average = 4, rare
factor = 4, FOV= 36 x 30mm, matrix size =256 x 256, each taking
4min and 48 s. All scans were carried out using Paravision 4.0
software (Bruker BioSpin Billerica, MA, USA).
T1 maps were acquired using an RARE-VTR sequence with
TRs = 29.447, 632.50, 1656.89 and 7500ms. TE= 6.567ms and RARE
factory =2. FOV= 4 x 4 cm, matrix =128 x 128, number of slices =1
and slice thickness = 1.5mm. T1-maps were made using PV5.1.
RESULTS
PEG-HCCs can function as immunomodulators
Previous work has shown that PEG-HCCs can scavenge radicals
and lower ROS levels in vivo after traumatic brain injury (8,9). How-
ever, no data has been shown on their immunomodulatory charac-
teristics. We chronically treated C57Bl/6 J mice with PEG-HCCs or
vehicle once a week over a 5-week period. At week 4, we carried
out a DTH assay, which assesses the recall immune response to a
specific antigen; OVA was used here. We found that chronic treat-
ment with PEG-HCCs resulted in decreased inflammation when
compared to saline-treated mice as shown in Fig. 1. Our results
demonstrate that chronic treatment with PEG-HCCs once a week,
for five total treatments, have immunomodulatory effects by
reducing an antigen-specific recall response in an in vivo system.
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Addition of Gadolinium changes the T1-properties of
PEG-HCCs
For in vivo imaging, we utilized gadolinium along with the PEG-
HCCs, to generate [Gd]DTPA-PEG-HCCs. Using a T1-weighted
protocol, we were able to show that [Gd]DTPA-PEG-HCCs (tube
2) at 340mg/L had increased signal intensity as shown in Fig. 2
compared to a solution of PEG-HCCs alone (tube 1) at
690mg/L. The measurement of T1-times shows that addition of
the gadolinium moiety results in significantly lower T1-times for
the [Gd]DTPA-PEG-HCCs compared to PEG-HCC alone as shown
in the graphs in Fig. 2. Our next step was to measure the relaxivity
of the [Gd]DTPA-PEG-HCCs. At 9.4 T, the relaxivity of [Gd]DTPA
has been reported to be approximately 3.9 s1mmol1. We first
measured the relaxivity of PEG-HCCs alone and observed that
there is no concentration-dependent change in T1-time as shown
in the line graph in Fig. 3. With the addition of [Gd]DTPA to the
PEG-HCCs, however, we see a change in the T1-time that corre-
lates with the concentration of the [Gd]DTPA-PEG-HCC solution.
The slope of this line is 9.5mM1 s1 indicating the possibility
of 2–3-[Gd]DTPA moieties on each of the PEG-HCC molecules.
Our results demonstrate our ability to modify the PEG-HCCs
into T1-contrast agents and the potential of our [Gd]DTPA-PEG-
HCCs as MR-detectable agents, giving us a way to assess their
delivery and localization to biologically relevant locations.
Treatment with [Gd]DTPA-PEG-HCCs results in accumulation
in lymph nodes
It was previously shown that PEG-HCCs are rapidly cleared from
the body of mice. However, there is some initial accumulation in
the liver and spleen, but the lymph nodes were not investigated.
In fact, it has been shown that PEG-HCCs and similar particles are
cleared via the biliary pathway, and as expected, this results in
accumulate in the liver (10). The spleen is also highly
vascularized which allows for the accumulation within the
spleen. Interestingly, we discovered that the administration of
PEG-HCCs and [Gd]DTPA-PEG-HCCs, subcutaneously at the base
of the tail of mice, resulted in the high accumulation of [Gd]
DTPA-PEG-HCCs within the draining lymph nodes 24-h post-
injection. This can be seen in Fig. 4 where the accumulation of
the [Gd]DTPA-PEG-HCCs forms a distinctive black patterning
within the lymph node (see inset).
Ex vivo imaging of treated lymph nodes shows positive
contrast
Twenty-four hours after mice were injected subcutaneously at
the base of the tail with [Gd]DTPA-PEG-HCCs, their auxiliary
lymph nodes were carefully excised from the fat pad and em-
bedded into 1% agarose for imaging via MRI. [Gd]DTPA-PEG-
Figure 2. [Gd]DTPA-PEG-HCCs have increased signal intensity compared to PEG-HCCs alone. T1-weighted scans and T1-times of [Gd]DTPA-PEG-HCCs,
PEG-HCCs and appropriate controls were assessed in 0.2-mL tubes at room temperature. The signal intensity of phantoms containing [Gd]DTPA-PEG-
HCC is comparable to that of Magnavist® compared to that of phosphate-buffered (PBS), water or PEG-HCC alone. T1-times were also measured, and the
T1-times of [Gd]DTPA-PEG-HCC is also decreased compared to PEG-HCC alone. 1-PEG-HCC, 2-[Gd]DTPA-PEG-HCC, 3-Water, 4-PBS, 5-Magnevist (5 mM).
**p< 0.01, ***p< 0.001.
Figure 1. PEG-HCCs are immunomodulating. C57Bl/6 J mice were
treated chronically for a period of 5 weeks with either PEG-HCC or vehi-
cle. Ear swelling after OVA challenge shows that chronic treatment with
PEG-HCCs resulted in significantly reduced inflammation compared to
those treated with vehicle. *p< 0.05.
Figure 3. [Gd]DTPA-PEG-HCCs have increased relaxivity compared to
PEG-HCC alone. Relaxivity was measured using two different batches of
[Gd]DTPA-PEG-HCC. There was little variation to be seen within the two
samples, and the relaxivity was measured to be approximately
9.5mM1 s1 with a correlation coefficient of 0.9895. PEG-HCC alone,
however, did not show any concentration dependent changes in T1-times.
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HCC overnight imaging utilizing a T1-weighted scan showed an
increase in signal intensity along the same zones where [Gd]
DTPA-PEG-HCC accumulation was visualized as seen in Fig. 5.
We do not see this increase in signal intensity in the lymph
nodes from mice treated with vehicle indicating that the change
in signal intensity is as a result of accumulation of [Gd]DTPA-
PEG-HCCs.
In vivo imaging of treated mice shows positive contrast in
lymph nodes
We have seen that the [Gd]DTPA-PEG-HCCs can be visualized
in vitro within phantoms, ex vivo within lymph nodes after care-
ful removal of the surrounding fat tissue. We then sought to vi-
sualize them in vivo within the lymph nodes of C57Bl/6 J mice.
We were able to select a single slice through the center of the
lymph node. A band of increased signal intensity can be seen
along the edge of the lymph node similar to what was seen in
the excised lymph nodes, which we do not see in the lymph
node of a mouse treated with vehicle as shown in Fig. 6. Images
were normalized to a water phantom that was included in all im-
aging, and the application of a Gaussian filter was used to en-
hance this bright band seen in the [Gd]DTPA-PEG-HCC-treated
lymph node in Fig. 6. A plot graph of a line through each of
the lymph nodes shows the increased signal intensity along
the edge of the lymph node that we do not see in the vehicle-
treated one in Fig. 7.
[Gd]DTPA-PEG-HCCs can be detected around germinal cen-
ters of lymph nodes
We have shown that PEG-HCCs are immunomodulatory in that
they suppress an immune recall response to a specific antigen,
OVA, as shown by the DTH assay. Also, the [Gd]DTPA-PEG-HCCs
appear not to be present throughout the lymph nodes but rather
to localize a specific zone. As a result, we decided to carry out im-
munofluorescence staining for CD3, a T cell marker, and PEG for
the [Gd]DTPA-PEG-HCCs. Any co-localization of these antibodies
would indicate that our [Gd]DTPA-PEG-HCCs are being taken up
by T cells, which would be a novel finding on its own as T cell la-
beling with a T1 contrast agent has yet to be reported.
As seen in Fig 8, the [Gd]DTPA-PEG-HCCs localize in the cortex
around germinal centers within the lymph nodes. Although the
lymph node section taken from the vehicle-treated mouse did
not show any positive signal for PEG, as shown in Fig. 8b, a signal
was detected in the lymph nodes of [Gd]DTPA-PEG-HCCs-treated
mice, in an area outside the T cell zone suggesting the presence
of the nanomaterials in the lymphatics within draining lymph
nodes. A cartoon of the lymph node anatomy is shown in Fig. 8c.
We then assessed what happens to the T1 in the spleen after
treatment with [Gd]DTPA-PEG-HCCs. We determined using T1
mapping that there is a decrease in the T1 values in the spleen
of animals treated with [Gd]DTPA-PEG-HCCs compared to ani-
mals treated with saline (Fig. 9). The T1 maps of the spleen in mice
that were treated with [Gd]DTPA-PEG-HCCs were not uniform in-
dicating that only certain parts of the spleen were accumulating
the [Gd]DTPA-PEG-HCCs. Histograms of the T1 maps within the
spleen demonstrate a clear shift to lower T1 values in spleens
treated with Gd]DTPA-PEG-HCCs compared with vehicle (Fig. 9).
Figure 5. [Gd]DTPA-PEG-HCC-treated lymph nodes can be visualized
ex vivo with MRI. Lymph nodes were embedded in 1% agarose and were
imaged using T1-weighted MRI. Shown above are the [Gd]DTPA-PEG-HCC
treated lymph node (top), vehicle-treated lymph node (bottom), which
were both embedded in 1% agarose, and water in a PCR tube (middle).
The first column of images demonstrate that the [Gd]DTPA-PEG-HCC
treated lymph node shows increased T1-signal intensity along where
there is accumulation of [Gd]DTPA-PEG-HCC, while this increase in signal
is not observed in the vehicle-treated lymph node. This signal intensity
increase is further demonstrated with the application of a color map (sec-
ond column) has been applied to indicate increased levels of signal in-
tensity. The hotter (red) colors indicate higher T1-signal intensity,
wherea colder colors (blue) indicate a lower T1-signal intensity.
Figure 4. [Gd]DTPA-PEG-HCCs accumulate in draining lymph nodes.
Twenty-four hours post-injection, [Gd]DTPA-PEG-HCCs can be seen visu-
ally to accumulate in the draining lymph nodes (axiliary lymph nodes)
after subcutaneous injection at the base of the tail in C57Bl/6 J mice.
Figure 6. [Gd]DTPA-PEG-HCC accumulation can be seen in lymph
nodes. [Gd]DTPA-PEG-HCC-treated lymph nodes show a bright band
along their edge. Twenty-four hours post-injection, mice were imaged
using T1-weighed scans through their inguinal lymph nodes. Image (a.)
is is the lymph node of a vehicle-treated mouse, whereas image (b.) is
the lymph nodes from a [Gd]DTPA-PEG-HCC- treated mouse. Increased
signal intensity can be visualized along the edge of the [Gd]DTPA-PEG-
HCC- treated lymph node, however, no such signal intensity increase
can be discerned in the vehicle-treated lymph node.
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Figure 8. Accumulation of [Gd]DTPA-PEG-HCCs is seen in the lymph node cortex around the germination centers. [Gd]DTPA-PEG-HCCs (red) accumu-
late in the cortex, including the area surrounding germination centers within lymph nodes as shown in (a). This area is adjacent to the T-cell zone as
evidenced by positive CD3 staining (green). Positive [Gd]DTPA-PEG-HCC staining is absent in images taken from vehicle treated lymph nodes as shown
in (b). All images are 20X magnification. A schematic of the lymph node is shown in (c) to indicate relevant regions where positive [Gd]DTPA-PEG-HCC
staining was observed.
Figure 7. Plot profile through the lymph node shows increased signal intensity (SI) on the edge of the lymph node. An increase in SI can be seen along
the edge of the lymph node treated with [Gd]DTPA-PEG-HCC on the bottom compared to the vehicle-treated lymph node shown on the top. Images
were initially normalized to water phantom and then a Gaussian filter was applied to increase the contrast of the lymph nodes.
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We then used flow cytometry to determine if the [Gd]DTPA-PEG-
HCCs were accumulating within the T cell within the spleen.
PEG-HCCs accumulate in T cells of the spleen
Purified populations of T cells from the spleen (Fig. 10a) were
assessed for the presence of PEG-HCC (Fig. 10b). Within each
treatment group, intact and permeabilized T cells were both
assessed to determine if cells are internalizing PEG-HCC instead
of the nanomaterial simply binding to the cell surface.
Figure 10c quantifies this difference and shows, within the
PEG-HCC-treated group, a significantly greater PEG signal in
the permeabilized cells. This shows that PEG-HCCs are internal-
ized by T cells in the spleen. In conjunction with our data show-
ing that [Gd]DTPA-PEG-HCCs can be imaged in vivo by MR, this
demonstrates a great potential of [GD]DTPA-PEG-HCCs for T cell
tracking.
DISCUSSION
Previous work done by Bitner et al. showed the effectiveness of
PEG-HCCs in lowering oxidative stress in vitro and in vivo in a
rat model of traumatic brain injury (9). The use of PEG-HCCs as
a nanovector has also been demonstrated by loading them with
drugs for delivery (10). This allows for a two-hit treatment model
involving the drug that the PEG-HCCs are loaded with along with
their radical scavenging potential. In the same capacity, PEG-
HCCs have been shown to be targetable with the non-covalent
addition of antibodies to the sidewalls of the nanoparticle (10).
We identified several new facets of [Gd]DTPA-PEG-HCCs in this
study. These nanoantioxidants are (i) immunomodulatory in that
they can suppress recall immune response; (ii) accumulate within
lymph nodes in areas surrounding the germinal centers, (iii) are
internalized by splenic T cells; and (iv) can be visualized in vivo
via MRI by conjugation to a T1-contrast agent [GD]DTPA.
However, there are several challenges to being able to visual-
ize lymph nodes. First, MRI slice selection is a challenge as a re-
sult of the small size of murine lymph nodes. Second, their
positioning within the fat pads makes them candidates for sus-
ceptibility artifacts. Finally, as we are imaging live animals, the
breathing motion, paired with the small size of the lymphoid or-
gan we are attempting to visualize, add to the difficulty of ac-
quiring images free of motion artifacts. We were able to
visualize the general location of the [Gd]DTPA-PEG-HCCs in the
Figure 9. T1 maps of the spleen demonstrate lower T1 values in animals treated with [Gd]DTPA-PEG-HCC compared with saline. T1 maps of [Gd]DTPA-
PEG-HCC-treated mice show lower values in the spleens compared with those treated with saline. Twenty-four hours post-injection, mice were imaged
using T1-weighed scans through the spleens. Image (a) two mice treated with saline, (b) two mice treated with [Gd]DTPA-PEG-HCC. In column 1, ana-
tomical scans are presented. In column 2, T1 maps are presented. The insets are zoomed in views of the spleen for both sets of data. Column 3 is a
histogram generated in PV 5.1 within a region of interest in the spleen only. Note that the T1 values are shifted lower in the PEG-HCC-treated animals.
Decreases in the T1 can be visualized throughout the [Gd]DTPA-PEG-HCC-treated spleens although it is not uniform. The T1 maps do not demonstrate
nearly the degree of decreased T1 values in the vehicle-treated spleens as shown in the histograms.
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lymph nodes and observe that their localization coincides with
the cortex surrounding the germinal centers. The spleen, on
the other hand, demonstrated lower T1 values as shown by T1
mapping after treatment with [Gd]DTPA-PEG-HCCs. As we see
that PEG-HCC treatment has an effect on the recall response,
and we have shown that PEG-HCCs are internalized by splenic
T-cells, we can conclude that PEG-HCCs and [Gd]DTPA-PEG-HCCs
are internalized and can modulate the recall memory response.
This discovery of T cell uptake and modulation of the recall im-
mune response by PEG-HCCs is an additional feature of these
nanoantioxidants. Our findings give impetus to the possibility of
utilizing PEG-HCCs (and their modified forms) in the treatment
of inflammatory diseases in which oxidative stress is both an ini-
tiating and propagating factor. With this in mind, [Gd]DTPA-PEG-
HCCs will not only be able to modulate the T cell response, but we
will also have the ability to track whether the nanoantioxidants
are tracking to and staying at sites where they will be most effec-
tive. As a result, it is of the utmost importance to continue further
characterization of this nanoantioxidant in the treatment, and
possibly the prevention, of human inflammatory diseases.
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